Transcatheter aortic valve implantation

Review of current evidence

Philippe Genereux, Martin B. Leon

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Symptomatic severe aortic stenosis (AS) has a poor prognosis when treated medically and inevitably leads to an insidious functional deterioration, heart failure, and death [1]. Surgical aortic valve replacement (SAVR) is the current standard of care and is an accepted method to alleviate symptoms and prolong survival. For an array of reasons, approximately 30 % do not undergo SAVR [2]. However, since Dr. Alain Cribier pioneered the first transcatheter aortic valve replacement (TAVR) procedure in 2002 [3], this relatively new technique has been used extensively in over 40 countries accumulating to >50,000 implantations [4-19]. With results from the randomized PARTNER trial [20], TAVR has emerged as the standard of care for extremely high-risk or "inoperable" patients and is a valid alternative to surgery for selected high-risk but "operable" patients with symptomatic AS [21]. Currently, two different TAVR devices are widely available and used: the balloon-expandable Edwards SAPIEN Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA) and the self-expanding Medtronic CoreValve™ (Medtronic, Minneapolis, MN). Both devices received CE Mark approval for European commercial sale in 2007, and the Edwards SAPIEN valve received FDA pre-market approval in the USA in November 2011.

Original languageEnglish (US)
Title of host publicationMultimodality Imaging for Transcatheter Aortic Valve Replacement
PublisherSpringer-Verlag London Ltd
Pages3-17
Number of pages15
Volume9781447127987
ISBN (Electronic)9781447127987
ISBN (Print)1447127978, 9781447127970
DOIs
StatePublished - Nov 1 2014

Fingerprint

Aortic Valve Stenosis
Standard of Care
Aortic Valve
Surgical Instruments
Equipment and Supplies
Heart Valves
Heart Failure
Survival
Transcatheter Aortic Valve Replacement

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Genereux, P., & Leon, M. B. (2014). Transcatheter aortic valve implantation: Review of current evidence. In Multimodality Imaging for Transcatheter Aortic Valve Replacement (Vol. 9781447127987, pp. 3-17). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-2798-7_2
Genereux, Philippe ; Leon, Martin B. / Transcatheter aortic valve implantation : Review of current evidence. Multimodality Imaging for Transcatheter Aortic Valve Replacement. Vol. 9781447127987 Springer-Verlag London Ltd, 2014. pp. 3-17
@inbook{a47c13aac14c4e288bda7b0ded02c7ff,
title = "Transcatheter aortic valve implantation: Review of current evidence",
abstract = "Symptomatic severe aortic stenosis (AS) has a poor prognosis when treated medically and inevitably leads to an insidious functional deterioration, heart failure, and death [1]. Surgical aortic valve replacement (SAVR) is the current standard of care and is an accepted method to alleviate symptoms and prolong survival. For an array of reasons, approximately 30 {\%} do not undergo SAVR [2]. However, since Dr. Alain Cribier pioneered the first transcatheter aortic valve replacement (TAVR) procedure in 2002 [3], this relatively new technique has been used extensively in over 40 countries accumulating to >50,000 implantations [4-19]. With results from the randomized PARTNER trial [20], TAVR has emerged as the standard of care for extremely high-risk or {"}inoperable{"} patients and is a valid alternative to surgery for selected high-risk but {"}operable{"} patients with symptomatic AS [21]. Currently, two different TAVR devices are widely available and used: the balloon-expandable Edwards SAPIEN Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA) and the self-expanding Medtronic CoreValve™ (Medtronic, Minneapolis, MN). Both devices received CE Mark approval for European commercial sale in 2007, and the Edwards SAPIEN valve received FDA pre-market approval in the USA in November 2011.",
author = "Philippe Genereux and Leon, {Martin B.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1007/978-1-4471-2798-7_2",
language = "English (US)",
isbn = "1447127978",
volume = "9781447127987",
pages = "3--17",
booktitle = "Multimodality Imaging for Transcatheter Aortic Valve Replacement",
publisher = "Springer-Verlag London Ltd",

}

Genereux, P & Leon, MB 2014, Transcatheter aortic valve implantation: Review of current evidence. in Multimodality Imaging for Transcatheter Aortic Valve Replacement. vol. 9781447127987, Springer-Verlag London Ltd, pp. 3-17. https://doi.org/10.1007/978-1-4471-2798-7_2

Transcatheter aortic valve implantation : Review of current evidence. / Genereux, Philippe; Leon, Martin B.

Multimodality Imaging for Transcatheter Aortic Valve Replacement. Vol. 9781447127987 Springer-Verlag London Ltd, 2014. p. 3-17.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Transcatheter aortic valve implantation

T2 - Review of current evidence

AU - Genereux, Philippe

AU - Leon, Martin B.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Symptomatic severe aortic stenosis (AS) has a poor prognosis when treated medically and inevitably leads to an insidious functional deterioration, heart failure, and death [1]. Surgical aortic valve replacement (SAVR) is the current standard of care and is an accepted method to alleviate symptoms and prolong survival. For an array of reasons, approximately 30 % do not undergo SAVR [2]. However, since Dr. Alain Cribier pioneered the first transcatheter aortic valve replacement (TAVR) procedure in 2002 [3], this relatively new technique has been used extensively in over 40 countries accumulating to >50,000 implantations [4-19]. With results from the randomized PARTNER trial [20], TAVR has emerged as the standard of care for extremely high-risk or "inoperable" patients and is a valid alternative to surgery for selected high-risk but "operable" patients with symptomatic AS [21]. Currently, two different TAVR devices are widely available and used: the balloon-expandable Edwards SAPIEN Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA) and the self-expanding Medtronic CoreValve™ (Medtronic, Minneapolis, MN). Both devices received CE Mark approval for European commercial sale in 2007, and the Edwards SAPIEN valve received FDA pre-market approval in the USA in November 2011.

AB - Symptomatic severe aortic stenosis (AS) has a poor prognosis when treated medically and inevitably leads to an insidious functional deterioration, heart failure, and death [1]. Surgical aortic valve replacement (SAVR) is the current standard of care and is an accepted method to alleviate symptoms and prolong survival. For an array of reasons, approximately 30 % do not undergo SAVR [2]. However, since Dr. Alain Cribier pioneered the first transcatheter aortic valve replacement (TAVR) procedure in 2002 [3], this relatively new technique has been used extensively in over 40 countries accumulating to >50,000 implantations [4-19]. With results from the randomized PARTNER trial [20], TAVR has emerged as the standard of care for extremely high-risk or "inoperable" patients and is a valid alternative to surgery for selected high-risk but "operable" patients with symptomatic AS [21]. Currently, two different TAVR devices are widely available and used: the balloon-expandable Edwards SAPIEN Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA) and the self-expanding Medtronic CoreValve™ (Medtronic, Minneapolis, MN). Both devices received CE Mark approval for European commercial sale in 2007, and the Edwards SAPIEN valve received FDA pre-market approval in the USA in November 2011.

UR - http://www.scopus.com/inward/record.url?scp=84930014285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930014285&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-2798-7_2

DO - 10.1007/978-1-4471-2798-7_2

M3 - Chapter

SN - 1447127978

SN - 9781447127970

VL - 9781447127987

SP - 3

EP - 17

BT - Multimodality Imaging for Transcatheter Aortic Valve Replacement

PB - Springer-Verlag London Ltd

ER -

Genereux P, Leon MB. Transcatheter aortic valve implantation: Review of current evidence. In Multimodality Imaging for Transcatheter Aortic Valve Replacement. Vol. 9781447127987. Springer-Verlag London Ltd. 2014. p. 3-17 https://doi.org/10.1007/978-1-4471-2798-7_2